Dupilumab for atopic dermatitis treatment: A single-center retrospective study

Creative Commons License

YAŞAR SUBAŞI G., BİLGİÇ A., YILMAZ E.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, sa.1, ss.12-16, 2022 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4274/turkderm.galenos.2021.36604
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.12-16
  • Anahtar Kelimeler: Atopic dermatitis, dupilumab, treatment, 2-PHASE 3 TRIALS, PLACEBO, MANAGEMENT, ADULTS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background and Design: Atopic dermatitis (AD) is a common chronic, recurrent, and itchy inflammatory skin disease. Various therapeutic agents are available, but severe side effects may limit their usage. Recently, dupilumab, a human monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors, is approved and might be used in patients with resistant AD, with the permission of the Ministry of Health.